ABSTRACT
In 2020, SARS-CoV-2 impacted Georgia, USA. Georgia announced state-wide shelter-in-place on April 2 and partially lifted restrictions on April 27. We analyzed daily incidence of confirmed COVID-19 cases by reporting date, March 2-June 14, in Georgia, Metro Atlanta, and Dougherty County and estimate the time-varying reproduction number, Rt, using R package EpiEstim. The median Rt estimate in Georgia dropped from between 2 and 4 in mid-March, to <2 in late March, and around 1 from mid-April to mid-June. Regarding Metro Atlanta, Rt fluctuated above 1.5 in March and around 1 since April. In Dougherty County, the median Rt declined from around 2 in late March to 0.32 on April 26. In Spring 2020, SARS-CoV-2 transmission in Georgia declined likely because of social distancing measures. However, as restrictions were relaxed in late April, community transmission continued with Rt fluctuating around 1 across Georgia, Metro Atlanta, and Dougherty County as of mid-June.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GC acknowledges support from NSF grant 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program. ICHF acknowledges salary support from the National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (19IPA1908208). This article is not part of ICHF's CDC-sponsored projects.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Georgia Southern University Institutional Review Board made a nonhuman subjects determination for this project (H20364), under the G8 exemption category.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email addresses: km11200{at}georgiasouthern.edu (K. Muniz-Rodriguez); gchowell{at}gsu.edu (G. Chowell); jschwind{at}georgiasouthern.edu (J. S. Schwind); rf08112{at}georgiasouthern.edu (R. Ford); so01935{at}georgiasouthern.edu (S. K. Ofori); co05814{at}georgiasouthern.edu (C. A. Ogwara); md18742{at}georgiasouthern.edu (M. R. Davies); tj10163{at}georgiasouthern.edu (T. Jacobs); westerpants{at}gmail.com (C.-H. Cheung); lcowan{at}georgiasouthern.edu (L. Cowan); ahansen{at}georgiasouthern.edu (A. Hansen); cfung{at}georgiasouthern.edu (I. C.-H. Fung)
Disclaimer: The opinions expressed in this paper does not necessarily represent the official positions of the CDC or the United States Government.
Data Availability
All data used in the analysis is presented in the Supplementary Materials.